Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical Center explains the role of PD-L1 and TMB biomarkers in treating lung cancer with both single agent immuno-oncology (I-O) and I-O combinations.
The Role of PD-L1 and TMB Biomarkers
